The plasma concentration of activated protein C appears normal in patients with haemophilia

Haemophilia

Volumn 15, Issue 2, 2009, Pages 566-570

  Schulman, Sam ^a,b,d   Eelde, A ^a   Blomback M ^a   Stenflo, J ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

^c LUND UNIVERSITY   (Sweden)

^d HHS General Hospital   (Canada)

Author keywords

Activated protein C; Bleeding; Haemophilia; Phenotype

Indexed keywords

ACTIVATED PROTEIN C; PLASMINOGEN ACTIVATOR INHIBITOR 3;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE MUTATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; ENZYME ACTIVATION; FEMALE; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN C; THROMBIN;

EID: 63349111957     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01957.x     Document Type: Article

References (20)

1. Fuentes-Prior P, Iwanaga Y, Huber R et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-25.
2. Esmon CT, Xu J, Gu JM et al. Endothelial protein C receptor. Thromb Haemost 1999; 82: 251-8.
3. Petaja J, Manco-Johnson MJ. Protein C pathway in infants and children. Semin Thromb Hemost 2003; 29: 349-62.
4. Jackson CJ, Xue M. Activated protein C - an anticoagulant that does more than stop clots. Int J Biochem Cell Biol 2008; 3: 3.
5. Griffin JH, Fernandez JA, Gale AJ et al. Activated protein C. J Thromb Haemost 2007; 5: 73-80.
6. Strandberg K, Kjellberg M, Knebel R et al. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: Use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001; 86: 604-10.
7. Nilsson G, Strandberg K, Astermark J et al. The APC-PCI complex concentration predicts outcome of aortic surgery. Thromb Res 2007; 120: 237-44.
8. Strandberg K, Stenflo J, Nilsson C et al. APC-PCI complex concentration is higher in patients with previous venous thromboembolism with factor V Leiden. J Thromb Haemost 2005; 3: 2578-80.
9. Strandberg K, Astermark J, Bjorgell O et al. Complexes between activated protein C and protein C inhibitor measured with a new method: Comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 2001; 86: 1400-8.
10. Kolbel T, Strandberg K, Donath T et al. Activated protein C-protein C inhibitor complex in patients with abdominal aortic aneurysms: Is it associated with diameter and growth rate? Vasc Endovascular Surg 2008; 42: 135-40.
11. Bhiladvala P, Strandberg K, Stenflo J et al. Early identification of acute myocardial infarction by activated protein C-protein C inhibitor complex. Thromb Res 2006; 118: 213-9.
12. Schulman S, Eelde A, Holmstrom M et al. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008; 6: 1113-21.
13. Löfqvist T, Nilsson IM, Berntorp E et al. Haemophilia prophylaxis in young patients: A long-term follow-up. J Intern Med 1997; 241: 395-400.
14. Petterson H, Gilbert M. Musculoskeletal and Other Complications. Diagnostic Imaging in Hemophilia. Berlin: Springer-Verlag, 1985: 56-68.
15. Schulman S, Eelde A. Confusion around the official classification of arthropathy. Haemophilia 2007; 13: 117-9.
16. Blomback M, Konkle BA, Manco-Johnson MJ et al. Preanalytical conditions that affect coagulation testing, including hormonal status and therapy. J Thromb Haemost 2007; 5: 855-8.
17. Strandberg K, Svensson A, Stenflo J. Stabilyte tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor. Thromb Haemost 2003; 89: 947-9.
18. Vossen CY, Strandberg K, Stenflo J et al. No effect of the prothrombin G20210A mutation on protein C activation in a large kindred with type I protein C deficiency. Blood Coagul Fibrinolysis 2004; 15: 573-6.
19. Butenas S, Orfeo T, Kalafatis M et al. Peptidomimetic inhibitors for activated protein C: Implications for hemophilia management. J Thromb Haemost 2006; 4: 2411-6.
20. De Nanteuil G, Gloanec P, Beguin S et al. Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders. J Med Chem 2006; 49: 5047-50.